{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:51Z","timestamp":1782534471310,"version":"3.54.5"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> (<jats:ext-link>https:\/\/inplasy.com\/inplasy-protocol-1239-2\/<\/jats:ext-link>), identifier (INPLASY2020120143).<\/jats:p>","DOI":"10.3389\/fphar.2022.823530","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T06:53:46Z","timestamp":1652770426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Wen-Jun","family":"Gou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Providencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-hong","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0002-9343(03)00366-8","article-title":"Prevalence, Treatment, and Control of Hypertension in Chronic Hemodialysis Patients in the United States","volume":"115","author":"Agarwal","year":"2003","journal-title":"Am. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant Hypertension: Diagnosis, Evaluation, and Treatment: a Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1093\/ndt\/gfq781","article-title":"Global Variation in Renal Replacement Therapy for End-Stage Renal Disease","volume":"26","author":"Caskey","year":"2011","journal-title":"Nephrol. Dial. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-dependent ESRD (SPin-D): a Randomized, Placebo-Controlled, Multiple Dosage Trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The New Biology of Aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J. Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone Is Secure and Reduces Left Ventricular Hypertrophy in Hemodialysis Patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2174\/1570161115666170201113817","article-title":"Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence","volume":"15","author":"Georgianos","year":"2017","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0039-128x(96)00010-4","article-title":"Mineralocorticoids, Salt and High Blood Pressure","volume":"61","author":"G\u00f3mez-S\u00e1nchez","year":"1996","journal-title":"Steroids"},{"key":"B9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of Spironolactone on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Oligo-Anuric Hemodialysis Patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A Randomized Controlled Trial of the Effect of Spironolactone on Left Ventricular Mass in Hemodialysis Patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"Cd013109","DOI":"10.1002\/14651858.CD013109.pub2","article-title":"Aldosterone Antagonists for People with Chronic Kidney Disease Requiring Dialysis","volume":"2","author":"Hasegawa","year":"2021","journal-title":"Cochrane database Syst. Rev."},{"key":"B12","first-page":"151","article-title":"Cochrane Handbook: General Methods for Cochrane Reviews: Ch 7: Selecting Studies and Collecting Data","volume":"7","author":"Higgins","year":"2011","journal-title":"Cochrane Handbook For: Syst. Rev. Interventions"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term Effects of Spironolactone in Peritoneal Dialysis Patients","volume":"25","author":"Ito","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.14010\/j.cnki.wjyx.2019.08.012","article-title":"Spironolactone in Improving Cardiovascular Function in Patients on Hemodialysis","volume":"30","author":"Jie","year":"2019","journal-title":"Med. J. Chin. PAP."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2005.01.019","article-title":"K\/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients","volume":"45","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","article-title":"RAAS Escape: a Real Clinical Entity that May Be Important in the Progression of Cardiovascular and Renal Disease","volume":"5","author":"Lakkis","year":"2003","journal-title":"Curr. Hypertens. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yfrne.2018.06.004","article-title":"Exogenous Melatonin as a Treatment for Secondary Sleep Disorders: A Systematic Review and Meta-Analysis","volume":"52","author":"Li","year":"2019","journal-title":"Front. Neuroendocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies that Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study","volume":"18","author":"Lin","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/j.1523-1755.2004.00931.x","article-title":"Effect of Spironolactone on K(+) Homeostasis and ENaC Expression in Lymphocytes from Chronic Hemodialysis Patients","volume":"66","author":"Michea","year":"2004","journal-title":"Kidney Int."},{"key":"B22","first-page":"31","article-title":"Effect of Aromatherapy with Lavender on Sleep Quality Among Patients Undergoing Hemodialysis","volume":"18","author":"Najafi","year":"2014","journal-title":"J. Kashan Univ. Med Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/1470320315575849","article-title":"Cardiovascular Actions of Mineralocorticoid Receptor Antagonists in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"16","author":"Ng","year":"2015","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of Spironolactone on Dialysis Patients with Refractory Hypertension: a Randomized Controlled Study","volume":"16","author":"Ni","year":"2014","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.ajkd.2010.03.022","article-title":"Dietary Potassium Intake and Mortality in Long-Term Hemodialysis Patients","volume":"56","author":"Noori","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jacc.2013.09.057","article-title":"Mineralocorticoid Receptor Antagonists in Patients with End-Stage Renal Disease on Chronic Hemodialysis","volume":"63","author":"Pitt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-Analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0014-2999(01)01586-2","article-title":"Effects of Brain Mineralocorticoid Receptor Blockade on Blood Pressure and Renal Functions in DOCA-Salt Hypertension","volume":"436","author":"Rahmouni","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of Hyperkalaemia Consequent to Mineralocorticoid-Receptor Antagonist Therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.kint.2018.12.006","article-title":"The Safety of Mineralocorticoid Antagonists in Maintenance Hemodialysis Patients: Two Steps Forward","volume":"95","author":"Rossignol","year":"2019","journal-title":"Kidney IntApr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: a Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: a Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone Blockade and the Mineralocorticoid Receptor in the Management of Chronic Kidney Disease: Current Concepts and Emerging Treatment Paradigms","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","article-title":"Myocardial Production of Aldosterone and Corticosterone in the Rat. Physiological Regulation","volume":"273","author":"Silvestre","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1006\/jmcc.1999.0963","article-title":"Extra-adrenal Mineralocorticoids and Cardiovascular Tissue","volume":"31","author":"Slight","year":"1999","journal-title":"J. Mol. Cel Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.3969\/j.issn.1009-5519.2017.19.017","article-title":"Effect of Spironolactone on Cardiac Function, Dialysis Adequacy and Complications in Hemodialysis","volume":"33","author":"Song","year":"2017","journal-title":"J. Mod. Med. Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s1071-9164(96)80009-1","article-title":"Aldosterone Escape during Angiotensin-Converting Enzyme Inhibitor Therapy in Chronic Heart Failure","volume":"2","author":"Struthers","year":"1996","journal-title":"J. Card. Fail."},{"key":"B40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3969\/j.issn.1673-7245.2002.05.005","article-title":"Oxygen-derived Free Radicals in the Pathogenesis of Hypertension","volume":"10","author":"Sui","year":"2002","journal-title":"Chin. J. Hypertens."},{"key":"B41","first-page":"507","article-title":"A Prospective Double-Blind Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Spironolactone in Patients with Advanced Congestive Heart Failure on Continuous Ambulatory Peritoneal Dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"B42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/ndt\/gfl509","article-title":"Spironolactone in Chronic Hemodialysis Patients Improves Cardiac Function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.19435\/j.1672-1721.2019.08.027","article-title":"Effect of Spironolactone on Improving Cardiovascular Function in Hemodialysis Patients","volume":"28","author":"Tang","year":"2019","journal-title":"Med. Forum"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/HYPERTENSIONAHA.109.140038","article-title":"Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin","volume":"54","author":"Tian","year":"2009","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3969\/j.issn.1671-4091.2016.05.005","article-title":"Comparison of the Efficacy of Lanthanum Carbonate and Calcium Acetate with Low Phosphorus Dietary on Hyperphosphatemia Among Patients on Peritoneal Dialysis","volume":"15","author":"Tian","year":"2016","journal-title":"Chin. J. Blood Purif."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-media Thickness in Nondiabetic Hemodialysis Patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.16766\/j.cnki.issn.1674-4152.000358","article-title":"Effects of Spironolactone on Cardiac and Residual Renal Function in Patients with Peritoneal Dialysis","volume":"16","author":"Wang","year":"2018","journal-title":"Chin. Gen. Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3969\/j.issn.1671-4091.2013.03.014","article-title":"Hypertension in Dialysis Patients-A Non-volume-dependent Factor","volume":"1","author":"Xu","year":"2013","journal-title":"Chin. J. Blood Purif."},{"key":"B50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1744-9987.12219","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone for Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients","volume":"19","author":"Yongsiri","year":"2015","journal-title":"Ther. Apher. Dialfeb"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.cir.102.22.2700","article-title":"Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients with Congestive Heart Failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"B52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3109\/0886022X.2016.1149684","article-title":"Safety and Cardiovascular Effects of Mineralocorticoid Receptor Antagonists for Patients Receiving Hemodialysis: a Systematic Review and Meta-Analysis","volume":"38","author":"Zhao","year":"2016","journal-title":"Ren. Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1681\/asn.v12122768","article-title":"Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis","volume":"12","author":"Zoccali","year":"2001","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.823530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T06:54:01Z","timestamp":1652770441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.823530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":54,"alternative-id":["10.3389\/fphar.2022.823530"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.823530","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"823530"}}